{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.6","upperLimit":"2.7","value":"1.9"},{"groupId":"OG001","lowerLimit":"1.7","upperLimit":"3.4","value":"1.9"},{"groupId":"OG002","lowerLimit":"0.8","upperLimit":"1.9","value":"1.6"},{"comment":"Not estimable due to insufficient number of participants with events.","groupId":"OG003","lowerLimit":"1.6","upperLimit":"NA","value":"1.9"},{"comment":"Not estimable due to insufficient number of participants with events.","groupId":"OG004","lowerLimit":"1.3","upperLimit":"NA","value":"3.4"},{"groupId":"OG005","lowerLimit":"1.6","upperLimit":"1.9","value":"1.8"},{"groupId":"OG006","lowerLimit":"1.5","upperLimit":"2.3","value":"1.9"},{"comment":"Not estimable due to insufficient number of participants with events.","groupId":"OG007","lowerLimit":"1.6","upperLimit":"NA","value":"2.8"},{"comment":"Not estimable due to insufficient number of participants with events.","groupId":"OG008","lowerLimit":"1.6","upperLimit":"NA","value":"2.6"},{"groupId":"OG009","lowerLimit":"1.0","upperLimit":"2.0","value":"1.8"},{"comment":"Not estimable due to insufficient number of participants with events.","groupId":"OG010","lowerLimit":"1.4","upperLimit":"NA","value":"1.5"},{"comment":"Not estimable due to insufficient number of participants with events.","groupId":"OG011","lowerLimit":"1.3","upperLimit":"NA","value":"3.8"},{"comment":"Not estimable due to insufficient number of participants with events.","groupId":"OG012","lowerLimit":"1.8","upperLimit":"NA","value":"4.2"},{"comment":"Not estimable due to insufficient number of participants with events.","groupId":"OG013","lowerLimit":"1.1","upperLimit":"NA","value":"2.6"},{"comment":"Not estimable due to insufficient number of participants with events.","groupId":"OG014","lowerLimit":"1.7","upperLimit":"NA","value":"8.4"},{"comment":"Not estimable due to insufficient number of participants with events.","groupId":"OG015","lowerLimit":"1.6","upperLimit":"NA","value":"1.8"},{"groupId":"OG016","lowerLimit":"2.0","upperLimit":"4.2","value":"2.8"},{"comment":"Not estimable due to insufficient number of participants with events.","groupId":"OG017","lowerLimit":"0.6","upperLimit":"NA","value":"7.5"},{"groupId":"OG018","lowerLimit":"0.6","upperLimit":"1.8","value":"1.6"},{"groupId":"OG019","lowerLimit":"1.5","upperLimit":"2.5","value":"2.0"},{"groupId":"OG020","lowerLimit":"1.0","upperLimit":"5.0","value":"3.1"},{"groupId":"OG021","lowerLimit":"1.7","upperLimit":"9.1","value":"3.2"},{"comment":"Not estimable due to insufficient number of participants with events.","groupId":"OG022","lowerLimit":"0.9","upperLimit":"NA","value":"1.5"},{"groupId":"OG023","lowerLimit":"1.7","upperLimit":"4.2","value":"2.0"},{"groupId":"OG024","lowerLimit":"1.6","upperLimit":"7.6","value":"3.8"},{"groupId":"OG025","lowerLimit":"1.7","upperLimit":"5.8","value":"3.2"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"25"},{"groupId":"OG006","value":"24"},{"groupId":"OG007","value":"5"},{"groupId":"OG008","value":"6"},{"groupId":"OG009","value":"11"},{"groupId":"OG010","value":"5"},{"groupId":"OG011","value":"6"},{"groupId":"OG012","value":"6"},{"groupId":"OG013","value":"6"},{"groupId":"OG014","value":"5"},{"groupId":"OG015","value":"6"},{"groupId":"OG016","value":"20"},{"groupId":"OG017","value":"6"},{"groupId":"OG018","value":"12"},{"groupId":"OG019","value":"7"},{"groupId":"OG020","value":"6"},{"groupId":"OG021","value":"12"},{"groupId":"OG022","value":"6"},{"groupId":"OG023","value":"11"},{"groupId":"OG024","value":"6"},{"groupId":"OG025","value":"6"}],"units":"Participants"}],"title":"ROW"},{"categories":[{"measurements":[{"comment":"Not estimable due to insufficient number of participants with events.","groupId":"OG000","lowerLimit":"1.2","upperLimit":"NA","value":"1.8"},{"comment":"Not estimable due to insufficient number of participants with events.","groupId":"OG005","lowerLimit":"1.0","upperLimit":"NA","value":"1.8"},{"groupId":"OG006","lowerLimit":"1.2","upperLimit":"1.8","value":"1.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"6"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"},{"groupId":"OG009","value":"0"},{"groupId":"OG010","value":"0"},{"groupId":"OG011","value":"0"},{"groupId":"OG012","value":"0"},{"groupId":"OG013","value":"0"},{"groupId":"OG014","value":"0"},{"groupId":"OG015","value":"0"},{"groupId":"OG016","value":"0"},{"groupId":"OG017","value":"0"},{"groupId":"OG018","value":"0"},{"groupId":"OG019","value":"0"},{"groupId":"OG020","value":"0"},{"groupId":"OG021","value":"0"},{"groupId":"OG022","value":"0"},{"groupId":"OG023","value":"0"},{"groupId":"OG024","value":"0"},{"groupId":"OG025","value":"0"}],"units":"Participants"}],"title":"Japanese"}],"denoms":[{"counts":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"30"},{"groupId":"OG006","value":"30"},{"groupId":"OG007","value":"5"},{"groupId":"OG008","value":"6"},{"groupId":"OG009","value":"11"},{"groupId":"OG010","value":"5"},{"groupId":"OG011","value":"6"},{"groupId":"OG012","value":"6"},{"groupId":"OG013","value":"6"},{"groupId":"OG014","value":"5"},{"groupId":"OG015","value":"6"},{"groupId":"OG016","value":"20"},{"groupId":"OG017","value":"6"},{"groupId":"OG018","value":"12"},{"groupId":"OG019","value":"7"},{"groupId":"OG020","value":"6"},{"groupId":"OG021","value":"12"},{"groupId":"OG022","value":"6"},{"groupId":"OG023","value":"11"},{"groupId":"OG024","value":"6"},{"groupId":"OG025","value":"6"}],"units":"Participants"}],"description":"PFS is the time from the date of start of treatment to the date of event defined as the first documented progression or death due to any cause. If a patient has not had an event, PFS is censored at the date of last adequate tumor assessment.\n\nTumor response was based on local investigator assessment and the assessment criteria was irRC.\n\nPFS is reported for ROW and Japanese patients.","dispersionType":"90% Confidence Interval","groups":[{"description":"Single-agent LAG525 1 mg/kg Q2W","id":"OG000","title":"Phase 1: LAG525 1 mg/kg Q2W"},{"description":"Single-agent LAG525 3 mg/kg Q2W","id":"OG001","title":"Phase 1: LAG525 3 mg/kg Q2W"},{"description":"Single-agent LAG525 5 mg/kg Q2W","id":"OG002","title":"Phase 1: LAG525 5 mg/kg Q2W"},{"description":"Single-agent LAG525 10 mg/kg Q2W","id":"OG003","title":"Phase 1: LAG525 10 mg/kg Q2W"},{"description":"Single-agent LAG525 15 mg/kg Q2W","id":"OG004","title":"Phase 1: LAG525 15 mg/kg Q2W"},{"description":"Single-agent LAG525 240 mg Q2W","id":"OG005","title":"Phase 1: LAG525 240 mg Q2W"},{"description":"Single-agent LAG525 400 mg Q2W","id":"OG006","title":"Phase 1: LAG525 400 mg Q2W"},{"description":"Single-agent LAG525 3 mg/kg Q4W","id":"OG007","title":"Phase 1: LAG525 3 mg/kg Q4W"},{"description":"Single-agent LAG525 5 mg/kg Q4W","id":"OG008","title":"Phase 1: LAG525 5 mg/kg Q4W"},{"description":"Single-agent LAG525 10 mg/kg Q4W","id":"OG009","title":"Phase 1: LAG525 10 mg/kg Q4W"},{"description":"Single-agent LAG525 400 mg Q4W","id":"OG010","title":"Phase 1: LAG525 400 mg Q4W"},{"description":"Combination LAG525 0.3 mg/kg + PDR001 1 mg/kg (Q2W/Q2W)","id":"OG011","title":"Phase 1: LAG525 0.3 mg/kg Q2W + PDR001 1 mg/kg Q2W"},{"description":"Combination LAG525 1 mg/kg + PDR001 1 mg/kg (Q2W/Q2W)","id":"OG012","title":"Phase 1: LAG525 1 mg/kg Q2W + PDR001 1 mg/kg Q2W"},{"description":"Combination LAG525 80 mg + PDR001 80 mg (Q2W/Q2W)","id":"OG013","title":"Phase 1: LAG525 80 mg Q2W + PDR001 80 mg Q2W"},{"description":"Combination LAG525 80 mg + PDR001 240 mg (Q2W/Q2W)","id":"OG014","title":"Phase 1: LAG525 80 mg Q2W + PDR001 240 mg Q2W"},{"description":"Combination LAG525 240 mg + PDR001 240 mg (Q2W/Q2W)","id":"OG015","title":"Phase 1: LAG525 240 mg Q2W + PDR001 240 mg Q2W"},{"description":"Combination LAG525 240 mg + PDR001 300 mg (Q3W/Q3W)","id":"OG016","title":"Phase 1: LAG525 240 mg Q3W + PDR001 300 mg Q3W"},{"description":"Combination LAG525 400 mg + PDR001 300 mg (Q3W/Q3W)","id":"OG017","title":"Phase 1: LAG525 400 mg Q3W + PDR001 300 mg Q3W"},{"description":"Combination LAG525 600 mg + PDR001 300 mg (Q3W/Q3W)","id":"OG018","title":"Phase 1: LAG525 600 mg Q3W + PDR001 300 mg Q3W"},{"description":"Combination LAG525 80 mg + PDR001 240 mg (Q4W/Q4W)","id":"OG019","title":"Phase 1: LAG525 80 mg Q4W + PDR001 240 mg Q4W"},{"description":"Combination LAG525 400 mg + PDR001 400 mg (Q4W/Q4W)","id":"OG020","title":"Phase 1: LAG525 400 mg Q4W + PDR001 400 mg Q4W"},{"description":"Combination LAG525 800 mg + PDR001 400 mg (Q4W/Q4W)","id":"OG021","title":"Phase 1: LAG525 800 mg Q4W + PDR001 400 mg Q4W"},{"description":"Combination LAG525 1000 mg + PDR001 400 mg (Q4W/Q4W)","id":"OG022","title":"Phase 1: LAG525 1000 mg Q4W + PDR001 400 mg Q4W"},{"description":"Combination LAG525 80 mg + PDR001 400 mg (Q2W/Q4W)","id":"OG023","title":"Phase 1: LAG525 80 mg Q2W + PDR001 400 mg Q4W"},{"description":"Combination LAG525 240 mg + PDR001 400 mg (Q2W/Q4W)","id":"OG024","title":"Phase 1: LAG525 240 mg Q2W + PDR001 400 mg Q4W"},{"description":"Combination LAG525 300 mg + PDR001 400 mg (Q2W/Q4W)","id":"OG025","title":"Phase 1: LAG525 300 mg Q2W + PDR001 400 mg Q4W"}],"paramType":"MEDIAN","populationDescription":"All patients in phase 1 who received at least one full or partial dose of LAG525 or PDR001.","reportingStatus":"POSTED","timeFrame":"From start of treatment to first documented progression or death due to any cause, assessed up to 4.4 years","title":"Phase 1: Progression-free Survival (PFS) Per irRC","type":"SECONDARY","unitOfMeasure":"months"}